









Markets
/
Stocks
/
nasdaq-kros
/

Keros Therapeutics Inc

KROS

16.040USD

+0.420+2.69%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

651.47MMarket Cap

34.70P/E TTM



Keros Therapeutics Inc

16.040

+0.420+2.69%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

39 / 506

Overall Ranking

126 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

23.000

Target Price

+47.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.55M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 78.98.

Overvalued

The company’s latest PE is 44.69, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 46.16M shares, decreasing 14.03% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.62M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 9.22, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 18.17M, representing a year-over-year increase of 49002.70%, while its net profit experienced a year-over-year increase of 32.17%.

Score

Industry at a Glance

Previous score

9.22

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.31

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.79

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 3.40, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 43.52, which is -7.92% below the recent high of 40.07 and 331.56% above the recent low of -100.77.

Score

Industry at a Glance

Previous score

3.40

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 7.64, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Keros Therapeutics Inc is 22.50, with a high of 35.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

7.64

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

23.000

Target Price

+47.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Keros Therapeutics Inc

KROS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.32, which is equal to the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 16.47 and the support level at 14.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.32

Change

0.19

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.011

Neutral

RSI(14)

62.640

Neutral

STOCH(KDJ)(9,3,3)

72.937

Buy

ATR(14)

0.454

High Vlolatility

CCI(14)

161.487

Buy

Williams %R

5.752

Overbought

TRIX(12,20)

0.365

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

15.734

Buy

MA10

15.685

Buy

MA20

15.513

Buy

MA50

14.743

Buy

MA100

14.372

Buy

MA200

15.791

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 114.02%, representing a quarter-over-quarter increase of 15.39%. The largest institutional shareholder is The Vanguard, holding a total of 2.62M shares, representing 6.45% of shares outstanding, with 34.15% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Adar1 Capital Management LLC

5.39M

Pontifax Venture Capital

4.79M

Madison Avenue Partners LP

2.61M

The Vanguard Group, Inc.

Star Investors

2.57M

+31.59%

BlackRock Institutional Trust Company, N.A.

2.51M

+1.65%

Logos Global Management LP

2.00M

Nantahala Capital Management, LLC

1.51M

+64.67%

Tang Capital Management, LLC

1.10M

State Street Global Advisors (US)

1.30M

+8.24%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 2.98, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.